TORONTO and HOUSTON, June 11,
2020 /PRNewswire/ - Medicenna Therapeutics Corp.
("Medicenna" or the "Company") (TSX: MDNA) (OTCQB: MDNAF), a
clinical stage immuno-oncology company, today announced that
Dr. Fahar Merchant, President, CEO and Chairman of the Board
of Medicenna, will present a corporate overview at the Raymond
James 2020 Human Healthcare Innovation Conference on Thursday, June 18th, 2020, at
1:40 PM ET.
A live webcast of the presentation may be accessed at
https://kvgo.com/raymondjames/medicenna-therapeutics-june-2020. A
replay of the presentation will be available after the event by
visiting the Investor Relations section of Medicenna's website at
https://ir.medicenna.com/.
About Medicenna
Medicenna is a clinical stage
immunotherapy company focused on the development of novel, highly
selective versions of IL-2, IL-4 and IL-13 Superkines and first in
class Empowered Cytokines™ (ECs) for the treatment of a broad range
of cancers. Medicenna's lead IL4-EC, MDNA55, has completed a Phase
2b clinical trial for rGBM, the most
common and uniformly fatal form of brain cancer. MDNA55 has been
studied in five clinical trials involving 132 patients, including
112 adults with rGBM. MDNA55 has demonstrated compelling efficacy
and has obtained Fast-Track and Orphan Drug status from the FDA and
FDA/EMA respectively. Medicenna's long-acting IL2 Superkine asset,
MDNA11, is potentially a best-in-class next-generation IL-2 with
superior CD122 binding without CD25 affinity and therefore
preferentially stimulating cancer killing effector T cells and NK
cells when compared to competing IL-2 programs. It is anticipated
that MDNA11 will be ready for the clinic in 2021. For more
information, please visit www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects", "believes" and similar
expressions. All statements other than statements of historical
fact, included in this release, including, without limitation,
statements related to the future plans and objectives of the
Company, are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ
materially from the Company's expectations include the risks
detailed in the annual information form of the Company dated
May 14, 2020 and in other filings
made by the Company with the applicable securities regulators from
time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect and that study results could change over time
as the study is continuing to follow up all patients and new data
are continually being received which could materially change study
results. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
View original
content:http://www.prnewswire.com/news-releases/medicenna-to-present-at-raymond-james-human-healthcare-innovation-conference-301074330.html
SOURCE Medicenna Therapeutics Corp.